Ligand Pharmaceuticals (FRA:LGDN) Inventories, Finished Goods: €9.9 Mil (As of Mar. 2026)


FRA:LGDN Ligand Pharmaceuticals Inc FRA:LGDN
78 GF Score
Price €270.00
GF Value €151.93
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Ligand Pharmaceuticals Inventories, Finished Goods?

Ligand Pharmaceuticals FRA:LGDN -0.74% 78 Inventories, Finished Goods is €9.9 Mil as of Mar. 2026. GuruFocus rates FRA:LGDN with a GF Score™ of 78/100 and a GF Value™ of €151.93 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Ligand Pharmaceuticals's quarterly finished goods declined from Sep. 2025 (€8.2 Mil) to Dec. 2025 (€0.0 Mil) but then increased from Dec. 2025 (€0.0 Mil) to Mar. 2026 (€9.9 Mil).

Ligand Pharmaceuticals Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Ligand Pharmaceuticals's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ligand Pharmaceuticals Inventories, Finished Goods Chart

Ligand Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Ligand Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.93 11.18 8.18 0.00 9.92
FRA:LGDN
78GF Score
Ligand Pharmaceuticals Inc FRA:LGDN
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ligand Pharmaceuticals Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of €9.9 Mil mean?
Ligand Pharmaceuticals (FRA:LGDN) has a Inventories, Finished Goods of €9.9 Mil as of Mar. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on Ligand Pharmaceuticals and its competitors.
Is Ligand Pharmaceuticals' Inventories, Finished Goods too high?
Ligand Pharmaceuticals' current Inventories, Finished Goods is €9.9 Mil. Overall, Ligand Pharmaceuticals has a GF Score™ of 78/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ligand Pharmaceuticals' Inventories, Finished Goods compare to DFTX and CGON?
Ligand Pharmaceuticals' Inventories, Finished Goods of €9.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Biotechnology company?
A good Inventories, Finished Goods depends on the Biotechnology industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Ligand Pharmaceuticals and its competitors. Ligand Pharmaceuticals's current Inventories, Finished Goods is €9.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ligand Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ligand Pharmaceuticals (FRA:LGDN) is currently considered Significantly Overvalued. The stock's GF Value™ is €151.93, compared to a current price of €270.00 — trading 77.7% above its estimated fair value. The current Inventories, Finished Goods is €9.9 Mil. Ligand Pharmaceuticals' overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Ligand Pharmaceuticals (FRA:LGDN), the current Inventories, Finished Goods is €9.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ligand Pharmaceuticals (FRA:LGDN) Overvalued in 2026?

Based on GuruFocus' analysis, Ligand Pharmaceuticals stock appears to be overvalued. The current stock price of €270.00 is trading 77.7% above its estimated GF Value™ of €151.93. GuruFocus considers Ligand Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:LGDN:

  • Inventories, Finished Goods: €9.9 Mil
  • GF Value™: €151.93 vs. price of €270.00 (77.7% above fair value)
  • GF Score™: 78/100 with 5 warning signs

No single metric tells the full story. See the FRA:LGDN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ligand Pharmaceuticals Business Description

Other Exchanges LGND:USA
Address 555 Heritage Drive, Suite 200, Jupiter, FL, USA, 33458
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
78GF Score

Get the complete analysis for FRA:LGDN

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€270.00
Price
€151.93
GF Value